Concepedia

Author

Thomas Bocan

Pfizer (United States)

Also Known As

T Bocan, T M Bocan, T. BOCAN, T. Bocan, T. M. A. BOCAN, T. M. A. Bocan, T.M.A. Bocan, Thomas Bocan, Thomas M A Bocan, Thomas M Bocan

76

Publications

3.3K

Citations

32

H-Index

105

Concepts

All Affiliations

Pfizer (United States)United States Army Medical Research Institute of Infectious DiseasesPennsylvania State UniversityWarde Medical LaboratoryNational Institutes of Health
TB

About

Thomas Bocan is an author at Pfizer (United States) specializing in medicine, pharmacology, and atherosclerosis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

26

33

2.2K

2

Biochemistry

12

12

606

3

Health Sciences

11

11

780

4

Natural Sciences

4

4

310

5

Public Health

2

2

100

Thomas Bocan

×

47

Publications

3.2K

Citations

31

H-Index

YearCitations

Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure

Janet T. Peterson, Hussein Hallak, Linda K. Johnson,

Circulation

2001

301

Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation.

Gary L. Cushing, John W. Gaubatz, M.L. Nava,

Arteriosclerosis An Official Journal of the American Heart Association Inc

1989

252

Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand

Lei Zhang, Anabella Villalobos, Elizabeth M. Beck,

Journal of Medicinal Chemistry

2013

199

Attenuation of diet‐induced atherosclerosis in rabbits with a highly selective 15‐lipoxygenase inhibitor lacking significant antioxidant properties

Sandra M. Sendobry, Joseph A. Cornicelli, Kathryn Welch,

British Journal of Pharmacology

1997

177

Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation.

Thomas Bocan, Sandra Bak Mueller, Paul D. Uhlendorf,

Arteriosclerosis and Thrombosis A Journal of Vascular Biology

1991

157

In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT.

BR Krause, Mitchell J. Anderson, C L Bisgaier,

Journal of Lipid Research

1993

148

A specific 15-lipoxygenase inhibitor limits the progression and monocyte–macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit

Thomas Bocan, Wendy S. Rosebury, Sandra Bak Mueller,

Atherosclerosis

1998

117

The relationship between the degree of dietary-induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation

Thomas Bocan, Sandra Bak Mueller, Paul D. Uhlendorf,

Atherosclerosis

1993

114

The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits

Thomas Bocan, Brian R. Krause, Wendy S. Rosebury,

Arteriosclerosis Thrombosis and Vascular Biology

2000

113

Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon

Darci R. Smith, Bradley S. Hollidge, Sharon P. Daye,

PLoS neglected tropical diseases

2017

107

Page 1